The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) added GARDASIL 9 to its list of recommended HPV vaccines, the nine-valent HPV vaccine's maker Merck said on Thursday.
The recommendations call for females between the ages of 9 and 26 and males between the ages of 9 and 21 receive the vaccine.
The CDC committee especially recommends the vaccine for people who have not yet received any HPV vaccine or finished the 3 doses.
Committee experts said GARDASIL 9 can be used to further or finish an HPV vaccination series for females and either GARDASIL or GARDASIL 9 can be used to further or finish the HPV vaccination series for males.
The U.S. Food and Drug Administration has not yet given approval of GARDASIL 9 specifically for people older than 16.
"The CDC has made increasing HPV vaccination rates a public health priority, and today's recommendation for GARDASIL 9 is an important milestone in the shared effort to help further reduce the burden of HPV-related cancers and diseases,” Merck Vaccines President Jacques Cholat said.